News
ARWR ▲ +1.8% - Arrowhead Pharmaceuticals, Inc.
ARWR ▲ +1.8% - Arrowhead Pharmaceuticals, Inc.
$ARWR - Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
07-OCT-2026 07:38 AM ET
Share this post
More filings for $ARWR
ARWR ▲ +1.8% - Arrowhead Pharmaceuticals, Inc.Oct 7, 2026ARWR ▲ +0.4% - Arrowhead Pharmaceuticals, Inc.Sep 15, 2026ARWR ▼ -0.8% - Arrowhead Pharmaceuticals, Inc.Sep 3, 2026ARWR ▼ -3.8% - Arrowhead Pharmaceuticals, Inc.Aug 30, 2026ARWR - Arrowhead Pharmaceuticals, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026$ARWR SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 31, 2026
View full $ARWR filing history →💬 Comments
Loading comments…
Leave a comment